<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956747</url>
  </required_header>
  <id_info>
    <org_study_id>2013/164</org_study_id>
    <nct_id>NCT01956747</nct_id>
  </id_info>
  <brief_title>Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies</brief_title>
  <acronym>OptiMal</acronym>
  <official_title>Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the presence of a Myelodysplastic Syndrome&#xD;
      (MDS) , Idiopathic Cytopenia of Undetermined Significance (ICUS) or Idiopathic Dysplasia of&#xD;
      Undetermined Significance (IDUS), correlates with treatment intensity and clinical outcome in&#xD;
      older patients with advanced malignancies receiving palliative chemotherapy. We will study&#xD;
      the relation between sarcopenia, comprehensive geriatric assessment en pharmacokinetics with&#xD;
      treatment related toxicity as well. We hypothesize that a standardized flow cytometry test to&#xD;
      determine bone marrow capacity, a Comprehensive Geriatric Assessment and/or measurement of&#xD;
      human body composition with computerized tomography will provide an accurate tool to optimize&#xD;
      treatment strategies in elderly patients with advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether the presence of a low - intermediate 1 risk MDS, IDUS or ICUS can predict for (myelo)toxicity in older patients with advanced malignancies receiving palliative chemotherapy</measure>
    <time_frame>from date of study inclusion until 30 days after end of treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Colorectum Advanced Malignancies</condition>
  <condition>Breast Advanced Malignancies</condition>
  <condition>Prostate Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>standard anticancer treatment</arm_group_label>
    <description>Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>venapunction</intervention_name>
    <arm_group_label>standard anticancer treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow punction</intervention_name>
    <arm_group_label>standard anticancer treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 70 years of age with advanced malignancies of colorectum, breast or&#xD;
        prostate, who will start with full standard anticancer treatment as decided by their&#xD;
        oncologist&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 70 years&#xD;
&#xD;
          -  Diagnosis of advanced cancer of colorectum, breast or prostate&#xD;
&#xD;
          -  Standard first line palliative treatment with cytotoxic agents will be started&#xD;
             (Folfox, Xelox, capecitabine, paclitaxel or docetaxel)&#xD;
&#xD;
          -  Estimated life expectancy ≥ 3 months&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  WHO performance status ≤ 2&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the treatment and follow-up schedule; those&#xD;
             conditions should be assessed with the patient before registration in the trial&#xD;
&#xD;
          -  No other severe medical or psychiatric conditions that in the judgment of the&#xD;
             investigator renders the patient inappropriate for inclusion in this study.&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given and documented to&#xD;
             ICH/EUCGCP, national/local regulatory requirements and the local rules followed in our&#xD;
             institution&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of cytopenia due to iron-, vitamin B12 and folic acid deficiency or&#xD;
             hemolysis, unless adequately supplemented.&#xD;
&#xD;
          -  Creatinine clearance ≤ 30 ml/min&#xD;
&#xD;
          -  Serum AST and ALT ≥ 2.5 x ULN, in case of liver metastases serum AST and ALT ≥ 5 x ULN&#xD;
&#xD;
          -  In case of therapy with Docetaxel/Paclitaxel serum bilirubin ≥ 1.5 x ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>K. Versteeg</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

